title: Collaborative study for the establishment of a European Phamacopoeia Biological reference preparation for Bordetella pertussis mouse antiserum for serological potency testing of acellular pertussis vaccines.
abstract: A collaborative study was organised by the European Directorate For the Quality of Medicines (EDQM) to assess the suitability of a candidate mouse antiserum as a European Pharmacopoeia Biological reference preparation (BRP) for acellular pertussis vaccine potency testing. The candidate antiserum was obtained by immunising mice with a five-component acellular pertussis vaccine: pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN) and Fimbrial 2/Fimbrial 3 (Fim 2&3). The study has been divided into two separate phases. Phase I was a pre-qualification study including three laboratories. This phase was aimed at pre-qualifying the candidate BRP (cBRP) and at documenting the impact of differences in the antibody detection methodology enzyme linked immunosorbent assay (ELISA) procedures on results of pertussis antisera calibration versus the currently used standard US standard pertussis antiserum (mouse) Lot 1 (SPAM-1) (United States Food and Drug Administration (USFDA) reference serum) and the cBRP. As no significant difference between the antibody titres determined by using the different ELISA methodologies was found, a large-scale study enrolling 13 laboratories (Phase II) was carried out, each participant performing its in-house methodology. Its aim was to calibrate the cBRP (in terms of the SPAM-1 reference) and to demonstrate its equivalence or superiority to internal references. The study showed that there was no difference in positive sera titres expressed relative to their corresponding internal reference (homologous situation) or the proposed standard (heterologous situation) reference. The cBRP can, therefore, reliably act as replacement for the in-house reference preparations. Further analysis of the outcome of this study enabled to assign to the cBRP a potency of 39, 138, 34 and 56 ELISA unit per millilitre, respectively, to its anti-PT, anti-FHA, anti-PRN and anti-Fim 2&3 antibody contents. The cBRP has been adopted by the European Pharmacopoeia Commission at its June 2000 session as Bordetella pertussis mouse anti-serum Ph Eur. BRP batch 1.
authors.affiliation: Agence Française de Sécurité Sanitaire des Produits de Santé, Site de Lyon, 321 avenue Jean Jaurès, 69007, Lyon, France. bertrand.poirier@afssaps.sante.fr
authors.forename: Bertrand
authors.initials: B
authors.lastname: Poirier
authors.forename: Nicole
authors.initials: N
authors.lastname: Bornstein
authors.forename: Murielle
authors.initials: M
authors.lastname: Andre
authors.forename: Denis
authors.initials: D
authors.lastname: Marmonier
authors.forename: Monique
authors.initials: M
authors.lastname: Pares
authors.forename: Gerard
authors.initials: G
authors.lastname: Vanhooren
authors.forename: Guy
authors.initials: G
authors.lastname: Rautmann
authors.forename: Marie-Emmanuelle
authors.initials: ME
authors.lastname: Behr-Gross
authors.forename: Roland
authors.initials: R
authors.lastname: Dobbelaer
authors.forename: Florence
authors.initials: F
authors.lastname: Fuchs
mesh_terms: D000818:Animals; D001886:Bordetella pertussis / Q000276:immunology*; D003299:Cooperative Behavior; D007106:Immune Sera / Q000276:immunology*; D051379:Mice; D010567:Pertussis Vaccine / Q000276:immunology*; D010602:Pharmacopoeias as Topic; D012015:Reference Standards
chemical_list: D007106:Immune Sera; D010567:Pertussis Vaccine